Ono Pharmaceutical Co Ltd 4528
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
-
Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma
-
Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion
-
Deciphera Pharmaceuticals Gets $2.4 Billion Buyout Offer From ONO Pharmaceutical
-
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma
-
FDA approves Pfizer's Braftovi plus Mektovi for a type of non-small cell lung cancer
Trading Information
- Previous Close Price
- ¥1,974.00
- Day Range
- ¥1,968.00–2,010.00
- 52-Week Range
- ¥1,893.00–2,849.00
- Bid/Ask
- ¥2,006.50 / ¥2,010.00
- Market Cap
- ¥943.76 Bil
- Volume/Avg
- 1.6 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- 7.96
- Price/Sales
- 1.91
- Dividend Yield (Trailing)
- 3.98%
- Dividend Yield (Forward)
- 3.98%
- Total Yield
- 9.28%
Company Profile
Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 3,853
- Website
- http://www.ono.co.jp
Comparables
Valuation
|
Metric
|
4528
|
4554
|
4506
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.96 | 11.58 | — |
Price/Book Value | 1.19 | 0.74 | 1.65 |
Price/Sales | 1.91 | 0.73 | 0.78 |
Price/Cash Flow | 6.80 | 4.54 | — |
Price/Earnings
4528
4554
4506
Financial Strength
|
Metric
|
4528
|
4554
|
4506
|
|---|---|---|---|
Quick Ratio | 3.29 | 0.55 | 0.26 |
Current Ratio | 3.99 | 1.24 | 0.52 |
Interest Coverage | 698.41 | 58.74 | −82.97 |
Quick Ratio
4528
4554
4506
Profitability
|
Metric
|
4528
|
4554
|
4506
|
|---|---|---|---|
Return on Assets (Normalized) | 15.67% | 4.98% | −13.24% |
Return on Equity (Normalized) | 18.10% | 10.16% | −41.15% |
Return on Invested Capital (Normalized) | 17.38% | 6.17% | −23.76% |
Return on Assets
4528
4554
4506
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Tnqlgfxjz | Thkz | $797.4 Bil | |||
| Johnson & Johnson
JNJ
| Fvtgxgjgp | Xjwc | $386.4 Bil | |||
| AbbVie Inc
ABBV
| Gxshmppl | Dvxy | $345.2 Bil | |||
| Merck & Co Inc
MRK
| Sgnlnbf | Psr | $279.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Xlngylrnhj | Pztt | $247.5 Bil | |||
| AstraZeneca PLC ADR
AZN
| Pdfcyxkmg | Jrpd | $246.0 Bil | |||
| Novartis AG ADR
NVS
| Mcflhqsm | Qjqjx | $232.2 Bil | |||
| Amgen Inc
AMGN
| Chbvgngxvr | Qpdxm | $170.6 Bil | |||
| Pfizer Inc
PFE
| Yvqzbcvkc | Nsgk | $160.6 Bil | |||
| Sanofi SA ADR
SNY
| Gxcrbrztf | Qxdz | $138.8 Bil |
United States